Resource Summary Report

Generated by RRID on Jul 30, 2026

Rictor (D16H9) Rabbit mAb

RRID:AB_10612959
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9476, RRID:AB_10612959

Antibody Information

URL: http://antibodyregistry.org/AB_10612959

Proper Citation: Cell Signaling Technology Cat# 9476, RRID:AB_10612959

Target Antigen: Rictor (D16H9) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, W-F

Antibody Name: Rictor (D16H9) Rabbit mAb

Description: This monoclonal targets Rictor (D16H9) Rabbit mAb

Target Organism: h, m, mouse, human

Antibody ID: AB_10612959

Vendor: Cell Signaling Technology

Catalog Number: 9476

Alternative Catalog Numbers: 9476S

Record Creation Time: 20250819T211712+0000

Record Last Update: 20250819T222744+0000

Ratings and Alerts

No rating or validation information has been found for Rictor (D16H9) Rabbit mAb.

No alerts have been found for Rictor (D16H9) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Fan J, et al. (2026) PDX1 phosphorylation at S61 by mTORC1 links nutrient signaling to ?? cell function and metabolic disease. Cell reports, 45(1), 116811.

Chen M, et al. (2023) Identification of XAF1 as an endogenous AKT inhibitor. Cell reports, 42(7), 112690.

Zhao Y, et al. (2023) mTORC2 orchestrates monocytic and granulocytic lineage commitment by an ATF5-mediated pathway. iScience, 26(9), 107540.

Dufour CR, et al. (2022) The mTOR chromatin-bound interactome in prostate cancer. Cell reports, 38(12), 110534.

McNamara MC, et al. (2022) Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. iScience, 25(11), 105458.

Torrence ME, et al. (2021) The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals. eLife, 10.

Cho S, et al. (2021) mTORC1 promotes cell growth via m6A-dependent mRNA degradation. Molecular cell, 81(10), 2064.

Villa E, et al. (2021) mTORC1 stimulates cell growth through SAM synthesis and m6A mRNA-dependent control of protein synthesis. Molecular cell, 81(10), 2076.

Brown WS, et al. (2020) Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer. Cell reports. Medicine, 1(8), 100131.

Harachi M, et al. (2020) Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM. Molecular cancer research : MCR, 18(8), 1142.

Wu R, et al. (2019) The Circadian Protein Period2 Suppresses mTORC1 Activity via Recruiting Tsc1 to mTORC1 Complex. Cell metabolism, 29(3), 653.

Meade N, et al. (2018) Poxviruses Evade Cytosolic Sensing through Disruption of an mTORC1-mTORC2 Regulatory Circuit. Cell, 174(5), 1143.

Bruning U, et al. (2018) Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation. Cell metabolism, 28(6), 866.

Yoon SO, et al. (2017) Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition. Molecular cell, 67(3), 512.

Gu Y, et al. (2017) mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Molecular cell, 67(1), 128.